Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study.

Saved in:
Bibliographic Details
Title: Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study.
Authors: Lin, Min‐Hsi1,2 (AUTHOR), Chu, Kuo‐An1,3 (AUTHOR), Chen, Chiu‐Fan1 (AUTHOR), Jiang, You‐Cheng1 (AUTHOR), Hong, Wei‐Cheng1 (AUTHOR), Hung, Ming‐Yen1 (AUTHOR), Hsu, Chun‐Hsiang1,4 (AUTHOR) benhsu740124@gmail.com
Source: Cancer Medicine. May2026, Vol. 15 Issue 5, p1-11. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 194013557
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Lin%2C+Min‐Hsi%22">Lin, Min‐Hsi</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chu%2C+Kuo‐An%22">Chu, Kuo‐An</searchLink><relatesTo>1,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chen%2C+Chiu‐Fan%22">Chen, Chiu‐Fan</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jiang%2C+You‐Cheng%22">Jiang, You‐Cheng</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hong%2C+Wei‐Cheng%22">Hong, Wei‐Cheng</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hung%2C+Ming‐Yen%22">Hung, Ming‐Yen</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hsu%2C+Chun‐Hsiang%22">Hsu, Chun‐Hsiang</searchLink><relatesTo>1,4</relatesTo> (AUTHOR)<i> benhsu740124@gmail.com</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Cancer+Medicine%22">Cancer Medicine</searchLink>. May2026, Vol. 15 Issue 5, p1-11. 11p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=194013557
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cam4.71881
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 1
    Titles:
      – TitleFull: Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lin, Min‐Hsi
      – PersonEntity:
          Name:
            NameFull: Chu, Kuo‐An
      – PersonEntity:
          Name:
            NameFull: Chen, Chiu‐Fan
      – PersonEntity:
          Name:
            NameFull: Jiang, You‐Cheng
      – PersonEntity:
          Name:
            NameFull: Hong, Wei‐Cheng
      – PersonEntity:
          Name:
            NameFull: Hung, Ming‐Yen
      – PersonEntity:
          Name:
            NameFull: Hsu, Chun‐Hsiang
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: May2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 20457634
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Cancer Medicine
              Type: main
ResultId 1